ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.8field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- The Next Frontier in Quantitative Co-Clinical Imaging to Advance Functional Precision Oncology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Development of Antibody and Antibody Fragment-Based Radiopharmaceuticals for Cancer Imaging and Therapy.Nuclear medicine and molecular imaging · 2026Review
- Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Antibody-drug conjugates in prostate cancer: current landscape and future directions.Therapeutic advances in medical oncology · 2026Review
- Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- The multiverse of CD46 and oncologic interactions.The Journal of clinical investigation · 2025Review
- Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer.Current oncology reports · 2025Review
- Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C-MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies.Cancer research · 2025Article
- Feasibility study of ADCs targeting TROP-2, HER2, and CD46 in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate.World journal of urology · 2024Article
- Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.Advanced healthcare materials · 2024Article
- CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- G-protein signaling of oxytocin receptor as a potential target for cabazitaxel-resistant prostate cancer.PNAS nexus · 2024Article
- Development of CD46 targeted alpha theranostics in prostate cancer usingTheranostics · 2024Article
- Actinium-225 targeted alpha particle therapy for prostate cancer.Theranostics · 2024Review
- Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future.Cancers · 2023Review
- Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- CD46 targetedJournal of experimental & clinical cancer research : CR · 2023Article
- PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 5 institutions in 2 countries.
Sinan Wang *Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-6282-1408
Jun Li *Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia.ORCID 0000-0002-7308-6576
Jun Hua *Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia.
Yang SuDepartment of Anesthesia, University of California, San Francisco, San Francisco, California.
Denis R Beckford-VeraDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Walter ZhaoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-8907-4935
Mayuri JayaramanDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Tony L HuynhDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-2964-1795
Ning ZhaoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-3699-3369
Yung-Hua WangDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-6282-1408
Yangjie HuangDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Fujun QinDepartment of Pathology, University of Virginia, Charlottesville, Virginia.ORCID 0000-0003-2337-7137
Sui ShenDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.ORCID 0000-0003-2708-6580
Daniel GioeliDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia.
Robert DreicerUniversity of Virginia Cancer Center, Charlottesville, Virginia.ORCID 0000-0002-0552-6912
Renuka SriramDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Emily A EgusaUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Jonathan ChouUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.ORCID 0000-0003-1258-0391
Felix Y FengUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Rahul AggarwalUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Michael J EvansDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-4947-1316
Youngho SeoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Bin LiuDepartment of Anesthesia, University of California, San Francisco, San Francisco, California. Robert.Flavell@ucsf.edu bin.liu@ucsf.edu jh6qv@virginia.edu.
Robert R FlavellDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California. Robert.Flavell@ucsf.edu bin.liu@ucsf.edu jh6qv@virginia.edu.
Jiang HeDepartment of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia. Robert.Flavell@ucsf.edu bin.liu@ucsf.edu jh6qv@virginia.edu.ORCID 0000-0001-7600-4604
University of California, San Francisco · USUniversity of Virginia · USChongqing Cancer Hospital · CNHuashan Hospital · CNUniversity of Alabama at Birmingham · US
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7MWomen's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1MNovel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancerR01CA223767 · NCI · UNIVERSITY OF VIRGINIA · PI HE, JIANG, LIU, BIN · 2018 to 2022
$2.8MTrimodal PET/SPECT/CT Preclinical Scanner for Biomedical ResearchS10OD021672 · OD · UNIVERSITY OF VIRGINIA · PI BERR, STUART S. · 2016 to 2016
$1.2MA novel immunoPET imaging agent to guide treatment planning in lethal prostate cancerR37CA251980 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FLAVELL, ROBERT RICHARD · 2021 to 2021
$662kNCI NIH HHS P30 CA044579NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA223767NCI NIH HHS R37 CA251980NIH HHS S10 OD021672
Abstract
purposeWe recently identified CD46 as a novel therapeutic target in prostate cancer. In this study, we developed a CD46-targeted PET radiopharmaceutical, [ EXPERIMENTAL
design[
results[
conclusions[
Indexed as
AdenocarcinomaAnimalsApoptosisCell ProliferationHumansImmunoconjugatesMaleMembrane Cofactor ProteinMiceMice, Inbred NODMice, NudeMice, SCIDMolecular ImagingNeuroendocrine TumorsPositron-Emission TomographyProstatic NeoplasmsCD46 protein, humanImmunoconjugatesMembrane Cofactor ProteinRadiopharmaceuticalsZirconium
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.